{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:46:21Z","timestamp":1792449981842,"version":"4.5.0"},"reference-count":55,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Diagnostic practices, awareness, and care delivery for gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) have evolved substantially. Contemporary epidemiologic data are needed to inform clinical practice and health-system planning.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine trends in incidence, overall survival (OS), and cancer-specific survival (CSS) for GEP-NENs over the past 2 decades.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This population-based, retrospective cohort study using linked administrative datasets included adults diagnosed with incident GEP-NENs in Ontario, Canada (2000-2023), with analysis from July to December 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n New diagnosis of a GEP-NEN, stratified by site (appendix, colon, pancreas, rectum, small intestine, or stomach).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Annual incidence per 100\u202f000 population was calculated. OS was estimated using Kaplan-Meier methods; CSS was estimated using cumulative incidence functions treating noncancer deaths as a competing risk. Factors associated with OS and CSS were assessed using multivariable Cox and Fine-Gray regression models, respectively.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 12\u202f877 individuals diagnosed with GEP-NENs with a median (IQR) age of 61 (50-71) years, 6228 (48.4%) were female. Synchronous metastases were present in 2313 individuals (16.5%). Overall incidence increased from 1.83 to 7.46 per 100\u202f000 between 2000 and 2023. Incidence was highest for small intestine primaries, followed by rectum, pancreas, appendix, stomach, and colon. The increase was almost entirely due to nonmetastatic disease (1.48 to 7.18 per 100\u202f000 per year, a 6.5-fold rise), with minimal change in metastatic presentations. The largest site-specific increases occurred in gastric and pancreatic NENs. Ten-year OS for all GEP-NENs was 63.3% (95% CI, 62.3%-64.3%). Ten-year CSS was 76.4% (95% CI, 75.6%-77.3%) for all GEP-NENs. CSS exceeded 90.0% at 10 years for patients without metastases at diagnosis but was 51.3% (95% CI, 49.7%-52.8%) for those with metastases at diagnosis. Survival estimates varied by primary tumor site, with most favorable outcomes for rectal and appendiceal NENs and least favorable for colonic and pancreatic NENs. Advancing age, lower socioeconomic status, and metastases at diagnosis were independently associated with worse OS and CSS, whereas female sex was associated with superior OS and CSS.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study of GEP-NENs found that incidence has continued to rise, largely due to increased diagnosis of nonmetastatic disease; OS and CSS were good but heterogeneous, influenced by demographic and disease-specific factors. These contemporary, population-based estimates provide essential evidence to support patient counselling, survivorship planning, health-system resource allocation, and the design of future NEN research.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.16492","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:30:33Z","timestamp":1780500633000},"page":"e2616492","source":"Crossref","is-referenced-by-count":3,"title":["Incidence and Survival of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in the Contemporary Era"],"prefix":"10.1001","volume":"9","author":[{"given":"Julie","family":"Hallet","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Toronto, Toronto, Ontario, Canada"},{"name":"Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"},{"name":"Cancer Program, ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9amarie","family":"Meloche-Dumas","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Sarzo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Court","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Toronto, Toronto, Ontario, Canada"},{"name":"Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Armah","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ding","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing C.","family":"Chan","sequence":"additional","affiliation":[{"name":"Cancer Program, ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Susan Leslie Clinic for Neuroendocrine Tumors, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Sunnybrook Research Institute, Toronto, Ontario, Canada"},{"name":"Cancer Program, ICES, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"1","key":"zoi260463r1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours.","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi260463r2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"18","key":"zoi260463r3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi260463r4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"zoi260463r5","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamaoncol.2017.0575","article-title":"Understanding neuroendocrine tumors\u2014a NET gain.","volume":"3","author":"Kunz","year":"2017","journal-title":"JAMA Oncol"},{"key":"zoi260463r6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.humpath.2024.06.015","article-title":"Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: association with recurrence risk, cellular phenotype, and heterogeneity.","volume":"150","author":"Yasunaga","year":"2024","journal-title":"Hum Pathol"},{"issue":"1","key":"zoi260463r7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms.","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"zoi260463r8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.humpath.2022.07.015","article-title":"The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.","volume":"129","author":"Heaphy","year":"2022","journal-title":"Hum Pathol"},{"issue":"28","key":"zoi260463r9","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group.","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi260463r10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors.","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi260463r11","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509).","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi260463r12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors.","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi260463r13","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1200\/JCO.2016.34.15_suppl.4005","article-title":"NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177Lu-DOTATATE.","volume":"34","author":"Strosberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10446","key":"zoi260463r14","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"zoi260463r15","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors.","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi260463r16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","article-title":"Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211).","volume":"41","author":"Kunz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi260463r17","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1245\/s10434-023-13372-z","article-title":"Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term follow-up evaluation of more than 500 patients.","volume":"30","author":"Gudmundsdottir","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"zoi260463r18","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1097\/SLA.0000000000004647","article-title":"Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis.","volume":"276","author":"Bennett","year":"2022","journal-title":"Ann Surg"},{"issue":"2","key":"zoi260463r19","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1245\/s10434-020-08784-0","article-title":"It is time to rethink biomarkers for surveillance of small bowel neuroendocrine tumors.","volume":"28","author":"Tran","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"zoi260463r20","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1245\/s10434-020-08787-x","article-title":"The landmark series: neuroendocrine tumor liver metastases.","volume":"27","author":"Gangi","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"zoi260463r21","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/bjs\/znac267","article-title":"Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2?cm: interim analysis of prospective ASPEN trial.","volume":"109","author":"Partelli","year":"2022","journal-title":"Br J Surg"},{"issue":"4","key":"zoi260463r22","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrae083","article-title":"Critical appraisal of the adequacy of surgical indications for non-functioning pancreatic neuroendocrine tumours.","volume":"8","author":"Partelli","year":"2024","journal-title":"BJS Open"},{"issue":"6","key":"zoi260463r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US.","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi260463r24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","article-title":"The reporting of studies conducted using observational routinely-collected health data (RECORD) statement.","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"5","key":"zoi260463r25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration.","volume":"41","author":"Robles","year":"1988","journal-title":"J Clin Epidemiol"},{"issue":"95","key":"zoi260463r26","first-page":"246","article-title":"Cancer registration in Ontario: a computer approach.","author":"Clarke","year":"1991","journal-title":"IARC Sci Publ"},{"issue":"1","key":"zoi260463r27","first-page":"91","article-title":"The hospital only project.","volume":"5","author":"Holowaty","year":"1993","journal-title":"Health Rep"},{"issue":"8","key":"zoi260463r28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.6004\/jnccn.2020.7666","article-title":"Risk of cancer-specific death for patients diagnosed with neuroendocrine tumors: a population-based analysis.","volume":"19","author":"Hallet","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"zoi260463r29","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/cncr.29338","article-title":"Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: a population-based analysis of 6271 cases.","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"zoi260463r30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"zoi260463r31","first-page":"33","article-title":"Measuring \u201crurality\u201d for purposes of health-care planning: an empirical measure for Ontario.","volume":"67","author":"Kralj","year":"2000","journal-title":"Ont Med Rev (Berl)"},{"issue":"8","key":"zoi260463r32","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1007\/BF03403823","article-title":"Development of the Canadian Marginalization Index: a new tool for the study of inequality.","volume":"103","author":"Matheson","year":"2012","journal-title":"Can J Public Health"},{"issue":"1","key":"zoi260463r33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12913-018-3125-7","article-title":"Validating an algorithm to identify metastatic gastric cancer in the absence of routinely collected TNM staging data.","volume":"18","author":"Mahar","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"zoi260463r34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40880-017-0218-3","article-title":"Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.","volume":"36","author":"Fang","year":"2017","journal-title":"Chin J Cancer"},{"issue":"27","key":"zoi260463r35","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.7150\/jca.32381","article-title":"Treatment patterns and survival among patients with metastatic gastroenteropancreatic neuroendocrine tumours in Sweden\u2014a population-based register-linkage and medical chart review study.","volume":"10","author":"Les\u00e9n","year":"2019","journal-title":"J Cancer"},{"issue":"1","key":"zoi260463r36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/MPA.0000000000001707","article-title":"Racial differences in gastroenteropancreatic neuroendocrine tumor treatment and survival in the United States.","volume":"50","author":"Kessel","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"zoi260463r37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00365521.2018.1553061","article-title":"Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.","volume":"54","author":"Gudmundsdottir","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"47","key":"zoi260463r38","doi-asserted-by":"publisher","first-page":"9012","DOI":"10.3748\/wjg.v19.i47.9012","article-title":"Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany.","volume":"19","author":"Scher\u00fcbl","year":"2013","journal-title":"World J Gastroenterol"},{"key":"zoi260463r39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1241724","article-title":"Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.","volume":"14","author":"Yao","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"zoi260463r40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ejca.2022.06.003","article-title":"Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study.","volume":"172","author":"Pole\u00e9","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi260463r41","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2018.36.4_suppl.231","article-title":"Incidence trends of gastroenteropancreatic neuroendocrine tumors in the United States from 1975 to 2012.","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi260463r42","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1093\/annonc\/mdt377","article-title":"Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study.","volume":"24","author":"Mocellin","year":"2013","journal-title":"Ann Oncol"},{"key":"zoi260463r44","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7150\/jca.4502","article-title":"Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis.","volume":"3","author":"Tsikitis","year":"2012","journal-title":"J Cancer"},{"issue":"8","key":"zoi260463r45","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/cancers13081753","article-title":"Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States.","volume":"13","author":"Shah","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"zoi260463r46","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.6004\/jnccn.2022.7075","article-title":"Incident cancer detection during multiple waves of COVID-19: the tsunami after the earthquake.","volume":"20","author":"Fu","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"zoi260463r47","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.gie.2021.03.932","article-title":"T1 rectal NET resection: does size really matter?","volume":"94","author":"Murino","year":"2021","journal-title":"Gastrointest Endosc"},{"issue":"10","key":"zoi260463r48","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.3390\/cancers15102766","article-title":"Optimising outcomes and surveillance strategies of rectal neuroendocrine neoplasms.","volume":"15","author":"Srirajaskanthan","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"zoi260463r49","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"issue":"10","key":"zoi260463r50","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacr.2010.06.013","article-title":"Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee.","volume":"7","author":"Berland","year":"2010","journal-title":"J Am Coll Radiol"},{"issue":"9","key":"zoi260463r51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2019.11456","article-title":"Trends in use of medical imaging in US health care systems and in Ontario, Canada, 2000-2016.","volume":"322","author":"Smith-Bindman","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"zoi260463r52","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1634\/theoncologist.2019-0112","article-title":"Patterns of symptoms burden in neuroendocrine tumors: a population-based analysis of prospective patient-reported outcomes.","volume":"24","author":"Hallet","year":"2019","journal-title":"Oncologist"},{"issue":"100510","key":"zoi260463r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100510","article-title":"Incidence and survival of neuroendocrine neoplasia in England 1995-2018: a retrospective, population-based study.","volume":"23","author":"White","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"13","key":"zoi260463r54","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.3390\/cancers16132376","article-title":"Sex differences in the survival of patients with neuroendocrine neoplasms: a comparative study of two national databases.","volume":"16","author":"Mortagy","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"zoi260463r55","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/jech-2019-213435","article-title":"Do men avoid seeking medical advice? A register-based analysis of gender-specific changes in primary healthcare use after first hospitalisation at ages 60+ in Denmark.","volume":"74","author":"H\u00f6hn","year":"2020","journal-title":"J Epidemiol Community Health"},{"key":"zoi260463r43","doi-asserted-by":"crossref","unstructured":"Yalcin? S, Turna? H, Shimon? I, . Gastroenteropancreatic neuroendocrine tumors (GEPNET) registry 2009-2018: a large multi-country registry with over 1000 GEPNET patients.? Research Square. Preprint posted online September 1, 2021. doi:10.21203\/rs.3.rs-827684\/v1?","DOI":"10.21203\/rs.3.rs-827684\/v1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849833\/hallet_2026_oi_260463_1779900745.02333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:30:35Z","timestamp":1780500635000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.16492","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}